Bruce Power announced the successful completion of the first Isotope Production System (IPS) installation within a commercial power reactor in the world; a collaborative project with Kinectrics. This milestone marks significant progress toward the production of the Lutetium-177 medical isotopes used in the treatment of neuroendocrine tumors and prostate cancer.

Isogen, the joint venture between Framatome and Kinectrics, developed irradiation capabilities to produce radioactive isotopes in one of Bruce Power's CANDU-type reactors. The process is based on a system of targets insertion and removal without interrupting the power generation of the reactor.

"Innovation is at the heart what we do. It is the momentum created by Framatome, Kinetrics and Bruce Power that enables us to celebrate this important milestone that contributes to the production of medical isotopes." said Francois Gauche, director of Framatome Healthcare.

"Through years dedicated to designing, testing and qualifying this innovative transport system, we contribute to improving the value of commercial nuclear reactors beyond providing reliable, low-carbon electricity generation. We look forward to supporting our partners at Kinectrics and Bruce Power as we move forward to provide irradiated targets to our other partner ITM for processing and distribution of Lu177 worldwide."

Related Links
Bruce Power
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com

Tweet

Thanks for being here; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor $5 Billed Once credit card or paypal		SpaceDaily Monthly Supporter $5 Billed Monthly paypal only

Framatome and General Atomics restart fuel fabrication facility for TRIGA reactors
Paris, France (SPX) Mar 19, 2022
Framatome and General Atomics recently celebrated the reopening of the fuel manufacturing facility dedicated to TRIGA research reactors. The renovations were done to support new requirements by the U.S. Department of Energy (US DOE). The facility received the authorization to restart from the French regulator ASN and resumed operation on December 20. Following an extensive renovation, this unique facility houses the latest industrial equipment and utilizes modernized processes to fabricate TRIGA f ... read more